Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBTC-MI-EVs
- Development stage
- Preclinical
- Lead developer
- Stemmedicare
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
MBTC-MI-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of heart failure and myocardial infarction. The drug utilizes Stemmedicare's proprietary immune-tolerized EV platform to facilitate cardiac repair and regeneration. By leveraging the natural signaling and cargo-delivery capabilities of EVs, the therapy aims to mitigate damage to cardiac tissue following an ischemic event and improve overall heart function. As of early 2024, the program is in the preclinical candidate stage of development.
Beyond the preview
Go deeper on MBTC-MI-EVs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBTC-MI-EVs.